Association of p53 codon 72 polymorphism with prostate cancer: a meta-analysis.

Relationship of prostate cancer with the polymorphism of p53 codon 72 was reported with inconsistent results. The purpose of this study was to quantitatively evaluate the association between p53 codon 72 polymorphism and prostate cancer susceptibility. We performed an extensive search of relevant studies and made a meta-analysis, including 8 studies with 815 prostate cancer cases and 1047 controls. The combined results showed that there were no significant differences in genotype distribution between prostate cancer cases and control on the basis of all studies, CC/GC versus GG (OR = 1.24, 95% CI: 0.93-1.65), GG/GC versus CC (OR = 0.96, 95% CI: 0.60-1.55), GC versus GG (OR = 1.27, 95% CI: 0.91-1.77), CC versus GG (OR = 1.25, 95% CI:0.74-2.12), GC versus CC (OR = 1.09, 95% CI: 0.63-1.87). When stratifying for the race, there were also no statistically significant differences in genotype distribution between prostate cancer cases and controls. This meta-analysis did not provide an evidence of confirming association between p53 codon 72 polymorphism and prostate cancer.